{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CDKN2A+Mutation", "query": { "condition": "CDKN2A Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CDKN2A+Mutation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:38:04.388Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02620839", "title": "Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pamela Munster", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2016-12-01", "completion_date": "2019-01-28", "has_results": false, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02620839" }, { "nct_id": "NCT02540876", "title": "Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm", "Solid Neoplasm", "Unresectable Malignant Neoplasm" ], "interventions": [ { "name": "Ilorasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-09-08", "completion_date": "2019-02-08", "has_results": false, "last_update_posted_date": "2019-04-22", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02540876" }, { "nct_id": "NCT07492680", "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab FDC", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-07-17", "completion_date": "2032-05-20", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 18, "location_summary": "San Francisco, California • Aurora, Colorado • Tampa, Florida + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492680" }, { "nct_id": "NCT02846935", "title": "p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "T-cell Lymphoma", "Aggressive B-cell Lymphoma", "Non-Hodgkin's Lymphomas", "Indolent B-cell Lymphoma" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Tetrahydrouridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yogen Saunthararajah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2017-04-25", "completion_date": "2018-01-22", "has_results": false, "last_update_posted_date": "2019-01-07", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02846935" }, { "nct_id": "NCT03435250", "title": "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "AG-270", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2018-03-04", "completion_date": "2023-04-20", "has_results": false, "last_update_posted_date": "2024-07-25", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435250" }, { "nct_id": "NCT02478320", "title": "Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Ilorasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2016-08-05", "completion_date": "2022-05-12", "has_results": true, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02478320" }, { "nct_id": "NCT03250078", "title": "A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "MRI/MRCP", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Nuvance Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 200, "start_date": "2016-11", "completion_date": "2030-11", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 1, "location_summary": "Norwalk, Connecticut", "locations": [ { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250078" }, { "nct_id": "NCT02187783", "title": "LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumors With CDK4/6 Pathway Activation" ], "interventions": [ { "name": "LEE011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2014-08-25", "completion_date": "2018-01-17", "has_results": true, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Pismo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187783" }, { "nct_id": "NCT04966481", "title": "Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HPV-unrelated Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2022-04-06", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 5, "location_summary": "Worthington, Minnesota • Kansas City, Missouri • St Louis, Missouri + 2 more", "locations": [ { "city": "Worthington", "state": "Minnesota" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04966481" }, { "nct_id": "NCT04074785", "title": "Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "GBM", "Glioblastoma", "Brain Tumor", "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2019-12-13", "completion_date": "2023-10-16", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-05-22T05:38:04.388Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04074785" } ] }